$MBRX
Moleculin Biotech, Inc. Stock $mbrx

$mbrx Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-K Financial Statement

#000165961718000027 Filed on March 28, 2018

Income Statement

Concept	2018 Q1	2017	2016 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.390M	$4.090M	$530.0K
YoY Change	63.53%	71.85%
% of Gross Profit
Research & Development	$1.237M	$4.545M	$880.0K
YoY Change	81.11%	203.81%
% of Gross Profit
Depreciation & Amortization	$8.000K	$18.00K	$10.00K
YoY Change	100.0%	200.0%
% of Gross Profit
Operating Expenses	$2.637M	$8.653M	$1.420M
YoY Change	71.79%	122.84%
Operating Profit	-$2.637M	-$8.653M
YoY Change	71.79%	122.84%
Interest Expense	$710.0K	$0.00	-$10.00K
YoY Change	70900.0%	-100.0%
% of Operating Profit
Other Income/Expense, Net	$0.00	$9.000K
YoY Change
Pretax Income	-$1.930M	-$9.810M	-$1.420M
YoY Change	484.85%	149.62%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.927M	-$9.805M	-$1.420M
YoY Change	485.71%	149.75%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$496.1K	-$3.175M	-$1.868M
COMMON SHARES
Basic Shares Outstanding	25.77M shares		12.05M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q1	2017	2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.11M	$7.710M	$5.010M
YoY Change	47.64%	53.89%
Cash & Equivalents	$13.11M	$7.710M	$5.007M
Short-Term Investments
Other Short-Term Assets	$630.0K	$590.0K	$220.0K
YoY Change	133.33%	168.18%
Inventory
Prepaid Expenses			$215.0K
Receivables
Other Receivables
Total Short-Term Assets	$13.75M	$8.300M	$5.222M
YoY Change	50.25%	59.0%	18489.58%
LONG-TERM ASSETS
Property, Plant & Equipment	$33.00K	$30.00K	$23.00K
YoY Change	65.0%	50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$11.18M	$11.18M	$11.17M
YoY Change	0.13%	0.09%
TOTAL ASSETS
Total Short-Term Assets	$13.75M	$8.300M	$5.222M
Total Long-Term Assets	$11.18M	$11.18M	$11.17M
Total Assets	$24.93M	$19.48M	$16.39M
YoY Change	22.7%	18.85%	58256.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$570.0K	$810.0K	$399.0K
YoY Change	-33.72%	-22.86%
Accrued Expenses	$766.0K	$900.0K	$650.0K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$300.0K
YoY Change		-100.0%
Total Short-Term Liabilities	$1.799M	$2.220M	$1.345M
YoY Change	-18.38%	64.44%	74.04%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.560M	$150.0K	$90.00K
YoY Change	29.95%	66.67%
Total Long-Term Liabilities	$2.560M	$150.0K	$90.00K
YoY Change	29.95%	66.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.799M	$2.220M	$1.345M
Total Long-Term Liabilities	$2.560M	$150.0K	$90.00K
Total Liabilities	$4.359M	$2.370M	$1.433M
YoY Change	4.28%	65.73%	85.43%
SHAREHOLDERS EQUITY
Retained Earnings	-$16.41M		-$4.675M
YoY Change			524.7%
Common Stock	$36.98M		$19.64M
YoY Change			294675.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$20.57M	$17.12M	$14.96M
YoY Change
Total Liabilities & Shareholders Equity	$24.93M	$19.48M	$16.39M
YoY Change	22.68%	18.85%	58256.77%

Cashflow Statement

Concept	2018 Q1	2017	2016 Q4
OPERATING ACTIVITIES
Net Income	-$1.927M	-$9.805M	-$1.420M
YoY Change	485.71%	149.75%
Depreciation, Depletion And Amortization	$8.000K	$18.00K	$10.00K
YoY Change	100.0%	200.0%
Cash From Operating Activities	-$2.807M	-$7.324M	-$1.160M
YoY Change	101.8%	94.53%
INVESTING ACTIVITIES
Capital Expenditures	$8.000K	$28.00K	-$10.00K
YoY Change		33.33%
Acquisitions		$0.00
YoY Change		-100.0%
Other Investing Activities		$0.00	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$8.000K	-$28.00K	-$10.00K
YoY Change		-76.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$8.215M	$10.06M	10.00K
YoY Change	56.03%	13.47%
NET CHANGE
Cash From Operating Activities	-$2.807M	-$7.324M	-1.160M
Cash From Investing Activities	-$8.000K	-$28.00K	-10.00K
Cash From Financing Activities	$8.215M	$10.06M	10.00K
Net Change In Cash	$5.400M	$2.707M	-1.160M
YoY Change	39.39%	-45.63%
FREE CASH FLOW
Cash From Operating Activities	-$2.807M	-$7.324M	-$1.160M
Capital Expenditures	$8.000K	$28.00K	-$10.00K
Free Cash Flow	-$2.815M	-$7.352M	-$1.150M
YoY Change	102.37%	94.19%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2017	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017	dei	Document Period End Date DocumentPeriodEndDate	2017-12-31
CY2017	dei	Document Type DocumentType	10-K
CY2017	dei	Entity Central Index Key EntityCentralIndexKey	0001659617
CY2017	dei	Amendment Flag AmendmentFlag	false
CY2017	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25768861	shares
CY2017	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2017Q2	dei	Entity Public Float EntityPublicFloat	32242351	USD
CY2017	dei	Entity Registrant Name EntityRegistrantName	Moleculin Biotech, Inc.
CY2017	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2017	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2017	dei	Trading Symbol TradingSymbol	MBRX
CY2016Q4	mbrx	Accrued Board Expenses Current AccruedBoardExpensesCurrent	91000	USD
CY2017Q4	mbrx	Accrued Board Expenses Current AccruedBoardExpensesCurrent	0	USD
CY2016Q4	mbrx	Accrued Clinical Testing Current AccruedClinicalTestingCurrent	238000	USD
CY2017Q4	mbrx	Accrued Clinical Testing Current AccruedClinicalTestingCurrent	320000	USD
CY2016Q4	mbrx	Accrued License Fees And Sra Current AccruedLicenseFeesAndSRACurrent	157000	USD
CY2017Q4	mbrx	Accrued License Fees And Sra Current AccruedLicenseFeesAndSRACurrent	260000	USD
CY2017	mbrx	Adjustmentsto Additional Paidin Capital Stock Issued Issuance Costs Atthe Market Offering AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsAttheMarketOffering	166000	USD
CY2017	mbrx	Adjustmentsto Additional Paidin Capital Stock Issued Issuance Costs Sale Of Units AdjustmentstoAdditionalPaidinCapitalStockIssuedIssuanceCostsSaleOfUnits	550000	USD
CY2017	mbrx	Adjustmentsto Additional Paidin Capital Stock Warrants Exercised During Period Issuance Costs AdjustmentstoAdditionalPaidinCapitalStockWarrantsExercisedDuringPeriodIssuanceCosts	73000	USD
CY2016Q2	mbrx	Business Acquisition Indemnification Agreement Term BusinessAcquisitionIndemnificationAgreementTerm	P6Y
CY2016	mbrx	Business Acquisition Pro Forma Earnings Per Share Basic And Diluted BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted	0.42
CY2016	mbrx	Business Acquisition Pro Forma Operating Expenses BusinessAcquisitionProFormaOperatingExpenses	3979000	USD
CY2016	mbrx	Business Acquisition Pro Forma Weighted Average Number Of Shares Outstanding Basic And Diluted BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted	9401028	shares
CY2016Q2	mbrx	Class Of Warrant Or Right Period From Which Warrants Or Rights Exercisable ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable	P5Y
CY2016Q1	mbrx	Debt Instrument Number Of Unsecured Notes Entered DebtInstrumentNumberOfUnsecuredNotesEntered	7	note
CY2016Q1	mbrx	Debt Instrument Unsecured Notes Number Of Third Party Investors DebtInstrumentUnsecuredNotesNumberOfThirdPartyInvestors	3	investor
CY2016Q4	mbrx	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	735000	USD
CY2017Q4	mbrx	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	1105000	USD
CY2016	mbrx	Deferred Tax Assets Valuation Allowance Releases DeferredTaxAssetsValuationAllowanceReleases	0	USD
CY2017	mbrx	Deferred Tax Assets Valuation Allowance Releases DeferredTaxAssetsValuationAllowanceReleases	0	USD
CY2016	mbrx	Effective Income Tax Rate Reconciliation Initial Public Offering Cost EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost	227000	USD
CY2017	mbrx	Effective Income Tax Rate Reconciliation Initial Public Offering Cost EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCost	76000	USD
CY2016	mbrx	Effective Income Tax Rate Reconciliation Initial Public Offering Cost Percent EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent	0.0578
CY2017	mbrx	Effective Income Tax Rate Reconciliation Initial Public Offering Cost Percent EffectiveIncomeTaxRateReconciliationInitialPublicOfferingCostPercent	0.0077
CY2016	mbrx	Effective Income Tax Rate Reconciliation Other Permanent Differences EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences	3000	USD
CY2017	mbrx	Effective Income Tax Rate Reconciliation Other Permanent Differences EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences	9000	USD
CY2016	mbrx	Effective Income Tax Rate Reconciliation Stock Warrant Costs EffectiveIncomeTaxRateReconciliationStockWarrantCosts	0	USD
CY2017	mbrx	Effective Income Tax Rate Reconciliation Stock Warrant Costs EffectiveIncomeTaxRateReconciliationStockWarrantCosts	395000	USD
CY2016	mbrx	Effective Income Tax Rate Reconciliation Other Permanent Differences Percent EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent	0.0008
CY2017	mbrx	Effective Income Tax Rate Reconciliation Other Permanent Differences Percent EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent	0.0009
CY2017	mbrx	Number Of Drug Technologies NumberOfDrugTechnologies	3	technology
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6000	USD
CY2017	mbrx	Number Of Other Drug Development Projects NumberOfOtherDrugDevelopmentProjects	2	project
CY2017	mbrx	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Aggregate Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedAggregateFairValue	1400000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	21000	USD
CY2017Q4	mbrx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue	0.13
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	19623000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	31577000	USD
CY2016	mbrx	Effective Income Tax Rate Reconciliation Stock Warrant Costs Percent EffectiveIncomeTaxRateReconciliationStockWarrantCostsPercent	0.0000
CY2017	mbrx	Effective Income Tax Rate Reconciliation Stock Warrant Costs Percent EffectiveIncomeTaxRateReconciliationStockWarrantCostsPercent	0.0403
CY2017	mbrx	Employee Agreements Special Termination Benefits Numberof Employees EmployeeAgreementsSpecialTerminationBenefitsNumberofEmployees	4	employee
CY2017	mbrx	Employee Agreements Termination Benefits Provided To Key Employees Aggregate Amount EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount	1000000	USD
CY2016	mbrx	Gain From Settlement Liability GainFromSettlementLiability	0	USD
CY2017	mbrx	Gain From Settlement Liability GainFromSettlementLiability	149000	USD
CY2016	mbrx	Gain Loss From Expiration Of Warrants GainLossFromExpirationOfWarrants	0	USD
CY2017	mbrx	Gain Loss From Expiration Of Warrants GainLossFromExpirationOfWarrants	1238000	USD
CY2016Q2	mbrx	Licensing Agreement Term LicensingAgreementTerm	P3Y
CY2016Q2	mbrx	Shares Authorized SharesAuthorized	80000000	shares
CY2017Q1	mbrx	Stock Issued During Period Shares For Cash Initial Public Offering Net Of Stock Issuance Costs StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts	3710000	shares
CY2016	mbrx	Stock Issued During Period Value For Cash Initial Public Offering Net Of Stock Issuance Costs StockIssuedDuringPeriodValueForCashInitialPublicOfferingNetOfStockIssuanceCosts	8089000	USD
CY2016	mbrx	Stock Issued During Period Value For Technology StockIssuedDuringPeriodValueForTechnology	3774000	USD
CY2017	mbrx	Stock Issued During Period Value New Issues Atthe Market Offering StockIssuedDuringPeriodValueNewIssuesAttheMarketOffering	1645000	USD
CY2016	mbrx	Stock Issued During Period Value Private Issuances StockIssuedDuringPeriodValuePrivateIssuances	703000	USD
CY2017	mbrx	Stock Issued During Period Value Sale Of Units StockIssuedDuringPeriodValueSaleOfUnits	317000	USD
CY2017	mbrx	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	8903000	USD
CY2016	mbrx	Stockholders Equity Subscriptions Settled For Cash StockholdersEquitySubscriptionsSettledForCash	3000	USD
CY2017Q4	mbrx	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Provisional Income Tax Expense Benefit TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit	0	USD
CY2016	mbrx	Warrants Issued For Services WarrantsIssuedForServices	375000	USD
CY2017	mbrx	Warrants Issued For Services WarrantsIssuedForServices	104000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	399000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	810000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	650000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	902000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	66000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	50000	USD
CY2016Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	84000	USD
CY2017Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	250000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	166000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	707000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1150000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	375000	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	324000	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	707000	USD
CY2016Q4	us-gaap	Assets Assets	16393000	USD
CY2017Q4	us-gaap	Assets Assets	19483000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	5222000	USD
CY2016Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	107802	shares
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7714000	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4979000	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2707000	USD
CY2016Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.50
CY2017Q4	us-gaap	Assets Current AssetsCurrent	8302000	USD
CY2016	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-3963000	USD
CY2016Q2	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	750000	USD
CY2016Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities	1000000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5007000	USD
CY2017Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	USD
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2016	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1401000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2565000	USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12164852	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21469109	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12164852	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21469109	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	12000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	21000	USD
CY2016Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	296000	USD
CY2017Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	USD
CY2016	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2016	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	364000	USD
CY2017	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	302000	USD
CY2016Q2	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	1166503	shares
	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	910095	shares
CY2016Q2	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	183356	USD
CY2016	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	155565	USD
CY2016	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	87000	USD
CY2017	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	62000	USD
CY2016Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	88000	USD
CY2017Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	150000	USD
CY2016	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	4000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	4000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	520000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	1275000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	50000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	9000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	96000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	176000	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4090000	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	2500000	USD
CY2017Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1240000	USD
CY2016	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1242000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1164000	USD
CY2017	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2548000	USD
CY2016	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
CY2017	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
CY2017	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.80
CY2016	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.013
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2381000	USD
CY2016	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	1560000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	155000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1400000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1397000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2560000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2561000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	4000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	4000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	4000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	4000	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6000	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	18000	USD
CY2016Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2017Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	503000	USD
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.40
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.53
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.3162
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.1187
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.1593
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0011
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0348
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0120
CY2017	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P8Y8M12D
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	1562000	USD
CY2016	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1335000	USD
CY2017	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	11000	USD
CY2016	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-137000	USD
CY2017	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	117000	USD
CY2016	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2017	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-41000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	411000	USD
CY2016	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	0	USD
CY2017	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	495000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	215000	USD
CY2017Q4	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	503000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8865000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10059000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-121000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-28000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3765000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7324000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-3926000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-9805000	USD
CY2017	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3334000	USD
CY2016	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	0	USD
CY2017	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	364000	USD
CY2016Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	11148000	USD
CY2017Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	11148000	USD
CY2016	us-gaap	Interest Expense InterestExpense	43000	USD
CY2017	us-gaap	Interest Expense InterestExpense	0	USD
CY2016	us-gaap	Interest Paid InterestPaid	5000	USD
CY2017	us-gaap	Interest Paid InterestPaid	3000	USD
CY2016Q4	us-gaap	Interest Payable Current InterestPayableCurrent	7172	USD
CY2016Q2	us-gaap	Interest Payable Current InterestPayableCurrent	17699	USD
CY2016Q4	us-gaap	Liabilities Liabilities	1433000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	2365000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16393000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19483000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1345000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2215000	USD
CY2017	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2016	us-gaap	Operating Expenses OperatingExpenses	3883000	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	8653000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-3883000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-8653000	USD
CY2017Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	6070000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	14000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	22000	USD
CY2016	us-gaap	Other Income OtherIncome	0	USD
CY2017	us-gaap	Other Income OtherIncome	9000	USD
CY2016	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2017	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	9000	USD
CY2017Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	588000	USD
CY2016	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	9170000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-14500000	USD
CY2016	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	100000	USD
CY2017	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	21000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	215000	USD
CY2017	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	6071000	USD
CY2016	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	165000	USD
CY2017	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2016	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2017	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3988000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	23000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	33000	USD
CY2016	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	470000	USD
CY2017	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1496000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4545000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4675000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-14480000	USD
CY2016	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
CY2017	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	324000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	707000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	50000	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.20
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	83000	USD
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	150000	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	460000	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	835000	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.75
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.59
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	275500	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.50
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.20
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.83
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.42
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y5M1D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	0.14
CY2017Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2015Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.14
CY2016	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1242000	USD
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1164000	USD
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9827510	shares
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18569193	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	83000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	200000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	510000	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1345000	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.20
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.28
CY2016Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	3.40
CY2017Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.93
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y3M15D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y26D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1800000	USD
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	3100000	USD
CY2016Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	3.00
CY2017Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.35
CY2016	us-gaap	Stock Issued1 StockIssued1	9774000	USD
CY2017	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	234297	shares
CY2016	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2017	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2016	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	5999000	USD
CY2016	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	364000	USD
CY2017	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	302000	USD
CY2016	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	158000	USD
CY2017	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	89000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	702894	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	-745000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	14960000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	17118000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2017	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Reclassifications</font><font style="font-family:inherit;font-size:10pt;"> - A reclassification was made to the December 31, 2016 financial statements to conform to the 2017 presentation. Such reclassification did not affect net loss as previously reported. Historically, "accrued expenses and current liabilities" were included in the line item "accounts payable and accrued expenses". Management believes that these costs are best shown as a separate line item and, as such, a reclassification was made to the balance sheet for the year ended December 31, 2016 by reducing "Accounts payable" and creating a new line item "Accrued expenses and current liabilities."</font></div></div>
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates in Financial Statement Presentation -</font><font style="font-family:inherit;font-size:10pt;"> The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001659617-18-000027-index-headers.html	Edgar Link	pending
0001659617-18-000027-index.html	Edgar Link	pending
0001659617-18-000027.txt	Edgar Link	pending
0001659617-18-000027-xbrl.zip	Edgar Link	pending
a2017q410-k.htm	Edgar Link	pending
a2017q410-kexhibit231.htm	Edgar Link	pending
a2017q410-kexhibit311.htm	Edgar Link	pending
a2017q410-kexhibit312.htm	Edgar Link	pending
a2017q410-kexhibit321.htm	Edgar Link	pending
a2017q410-kexhibit322.htm	Edgar Link	pending
cancerindustrychart.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
mbrx-20171231.xml	Edgar Link	completed
mbrx-20171231.xsd	Edgar Link	pending
mbrx-20171231_cal.xml	Edgar Link	unprocessable
mbrx-20171231_def.xml	Edgar Link	unprocessable
mbrx-20171231_lab.xml	Edgar Link	unprocessable
mbrx-20171231_pre.xml	Edgar Link	unprocessable
pg11img1_10k.jpg	Edgar Link	pending
pg13img1_10k.jpg	Edgar Link	pending
pg14img1_10k.jpg	Edgar Link	pending
pg1img1_10k.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
wp1122inmice.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MBRX
Moleculin Biotech, Inc. Stock $mbrx

2018 Q1 Form 10-K Financial Statement

#000165961718000027 Filed on March 28, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MBRX Moleculin Biotech, Inc. Stock $mbrx

2018 Q1 Form 10-K Financial Statement

#000165961718000027 Filed on March 28, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MBRX
Moleculin Biotech, Inc. Stock $mbrx